MA28240A1 - Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation - Google Patents
Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisationInfo
- Publication number
- MA28240A1 MA28240A1 MA29141A MA29141A MA28240A1 MA 28240 A1 MA28240 A1 MA 28240A1 MA 29141 A MA29141 A MA 29141A MA 29141 A MA29141 A MA 29141A MA 28240 A1 MA28240 A1 MA 28240A1
- Authority
- MA
- Morocco
- Prior art keywords
- methyl
- hypusin
- combination
- benzoylamido
- piperazino
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- -1 4-METHYL-PIPERAZINO-METHYL Chemical class 0.000 title abstract 2
- KDYRQBCJBKCHIQ-UHFFFAOYSA-N Hypusin Natural products NCC(O)CNCCCCC(N)C(=O)O KDYRQBCJBKCHIQ-UHFFFAOYSA-N 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000032839 leukemia Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53156303P | 2003-12-19 | 2003-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA28240A1 true MA28240A1 (fr) | 2006-10-02 |
Family
ID=34700180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA29141A MA28240A1 (fr) | 2003-12-19 | 2006-06-26 | Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080139480A1 (enExample) |
| EP (1) | EP1696917A1 (enExample) |
| JP (1) | JP2007514699A (enExample) |
| KR (1) | KR20060125810A (enExample) |
| CN (1) | CN1889952A (enExample) |
| AU (2) | AU2004298761A1 (enExample) |
| BR (1) | BRPI0417759A (enExample) |
| CA (1) | CA2547196A1 (enExample) |
| EC (1) | ECSP066656A (enExample) |
| IL (1) | IL176070A0 (enExample) |
| MA (1) | MA28240A1 (enExample) |
| MX (1) | MXPA06006925A (enExample) |
| NO (1) | NO20063326L (enExample) |
| RU (1) | RU2006125741A (enExample) |
| TN (1) | TNSN06182A1 (enExample) |
| WO (1) | WO2005058320A1 (enExample) |
| ZA (1) | ZA200603904B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2197440T3 (pl) | 2007-08-31 | 2013-05-31 | Janssen Pharmaceutica Nv | Kombinacje imazalilu i hydroksypirydonów |
| WO2009036753A2 (de) * | 2007-09-20 | 2009-03-26 | Schebo Biotech Ag | Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie |
| WO2009098243A1 (en) * | 2008-02-06 | 2009-08-13 | Janssen Pharmaceutica Nv | Combinations of anilinopyrimidines and pyrion compounds |
| WO2009098245A2 (en) | 2008-02-06 | 2009-08-13 | Janssen Pharmaceutica Nv | Combinations of phenylpyrroles and pyrion compounds |
| WO2010048712A1 (en) * | 2008-10-31 | 2010-05-06 | University Health Network | Ciclopirox and cytarabine for the treatment of leukemic disorders |
| CN104926722A (zh) * | 2010-06-01 | 2015-09-23 | 拜欧赛里克斯公司 | 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途 |
| MX342465B (es) * | 2010-06-01 | 2016-09-30 | Biotheryx Inc * | Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona. |
| EP2579718B1 (en) | 2010-06-10 | 2014-10-01 | Janssen Pharmaceutica, N.V. | Combinations of pyrimethanil and monoterpenes |
| JP5870101B2 (ja) | 2010-07-01 | 2016-02-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | ピリオン化合物とポリエチレンイミンとの抗微生物性組み合わせ |
| CN103191110A (zh) * | 2013-03-28 | 2013-07-10 | 中国科学院昆明植物研究所 | 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8528983D0 (en) * | 1985-11-25 | 1986-01-02 | Ciba Geigy Ag | Use of chelating agents |
| EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| ES2331562T3 (es) * | 2001-03-23 | 2010-01-08 | Enzon, Inc. | Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos. |
| WO2004007676A2 (en) * | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
-
2004
- 2004-12-17 JP JP2006544368A patent/JP2007514699A/ja active Pending
- 2004-12-17 CN CNA2004800362740A patent/CN1889952A/zh active Pending
- 2004-12-17 US US10/583,107 patent/US20080139480A1/en not_active Abandoned
- 2004-12-17 BR BRPI0417759-2A patent/BRPI0417759A/pt not_active IP Right Cessation
- 2004-12-17 EP EP04804040A patent/EP1696917A1/en not_active Withdrawn
- 2004-12-17 RU RU2006125741/14A patent/RU2006125741A/ru not_active Application Discontinuation
- 2004-12-17 AU AU2004298761A patent/AU2004298761A1/en not_active Abandoned
- 2004-12-17 KR KR1020067012061A patent/KR20060125810A/ko not_active Withdrawn
- 2004-12-17 MX MXPA06006925A patent/MXPA06006925A/es not_active Application Discontinuation
- 2004-12-17 CA CA002547196A patent/CA2547196A1/en not_active Abandoned
- 2004-12-17 WO PCT/EP2004/014439 patent/WO2005058320A1/en not_active Ceased
-
2006
- 2006-05-16 ZA ZA200603904A patent/ZA200603904B/en unknown
- 2006-05-31 IL IL176070A patent/IL176070A0/en unknown
- 2006-06-15 TN TNP2006000182A patent/TNSN06182A1/en unknown
- 2006-06-19 EC EC2006006656A patent/ECSP066656A/es unknown
- 2006-06-26 MA MA29141A patent/MA28240A1/fr unknown
- 2006-07-18 NO NO20063326A patent/NO20063326L/no not_active Application Discontinuation
-
2009
- 2009-04-28 AU AU2009201694A patent/AU2009201694A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009201694A1 (en) | 2009-05-28 |
| WO2005058320A1 (en) | 2005-06-30 |
| IL176070A0 (en) | 2006-10-05 |
| CA2547196A1 (en) | 2005-06-30 |
| BRPI0417759A (pt) | 2007-04-10 |
| NO20063326L (no) | 2006-09-19 |
| ECSP066656A (es) | 2006-10-25 |
| ZA200603904B (en) | 2007-09-26 |
| MXPA06006925A (es) | 2006-08-23 |
| TNSN06182A1 (en) | 2007-11-15 |
| RU2006125741A (ru) | 2008-01-27 |
| EP1696917A1 (en) | 2006-09-06 |
| JP2007514699A (ja) | 2007-06-07 |
| KR20060125810A (ko) | 2006-12-06 |
| AU2004298761A1 (en) | 2005-06-30 |
| CN1889952A (zh) | 2007-01-03 |
| US20080139480A1 (en) | 2008-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2448103C2 (ru) | Бициклические амиды как ингибиторы киназы | |
| ECSP034823A (es) | Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico | |
| ATE396731T1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| JP2005502643A5 (enExample) | ||
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| ATE365733T1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| MA28240A1 (fr) | Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation | |
| JP2003523325A5 (enExample) | ||
| TWI265930B (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases | |
| DE60323133D1 (de) | Cyclohexylverbindungen als ccr5-antagonisten | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60318891D1 (de) | Cyclopropylverbindungen als ccr5 antagonisten | |
| MY128051A (en) | Mesylate trihydrate salt of 5-(2-(4-(1, 2-benzisothiazol-3 -yl)-1-piperazinyl)ethyl)-6-chloro-1, 3-dihydro-2-(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist | |
| ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
| BR0312873A (pt) | 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante | |
| BG102892A (en) | Mesylate dihydrated salts of 5-(2-4(1,2-benzisothiazol-3-yl)-1-piperazinyl)-athyl)-6-chloro-1,3 -dihydro-2(1h)-indol-on(=ciprazidon), their preparation and application as dopamine d2 antagonists | |
| BG107468A (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases | |
| MY125768A (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases | |
| DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
| EP1266663A4 (en) | INDUCER OF EOSINOPHILIC SPECIFIC APOPTOSIS | |
| SE9902935D0 (sv) | Pharmaceutical compositions | |
| AR045330A1 (es) | Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla | |
| DE60212434D1 (de) | Rosiglitazon-edisylate und ihre verwendung als antidiabetika | |
| ECSP034469A (es) | Compuesto farmaceutico novedoso | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen |